Medofloran

Terbinafine, the active ingredient in Medofloran, is an allylamine antifungal presented as an oral dosage form for systemic use. It treats fungal infections of the skin, nails and related tissues in adult patients.

GNH USA supplies Medofloran as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Terbinafine is used to treat infections caused by dermatophytes and other fungi affecting the skin and nails.

- Onychomycosis: eradicates fungal growth in toenails and fingernails, improving nail appearance and health. - Tinea corporis: clears ring‑shaped skin lesions caused by dermatophyte infection. - Tinea pedis: relieves athlete’s foot symptoms and eliminates the causative fungus. - Tinea cruris: treats fungal infection of the groin area, reducing itching and redness.

Terbinafine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Skin rash or pruritus: localized itching or erythema. - Taste disturbance: altered taste perception or loss of taste. - Elevated liver enzymes: mild, transient increases in hepatic transaminases.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice or dark urine. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hematologic abnormalities: neutropenia or agranulocytosis. - Peripheral neuropathy: tingling or numbness in extremities. - Anaphylaxis: rare systemic allergic response requiring immediate medical attention.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Liver function assessment: obtain baseline hepatic enzymes and repeat if symptoms arise. - Hypersensitivity screening: avoid use in patients with known terbinafine allergy. - Renal impairment caution: adjust dosing in severe kidney disease. - Drug interaction vigilance: review concomitant medications that affect CYP pathways. - Pregnancy and lactation: safety data are limited; use only if benefit outweighs risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Terbinafine can alter the plasma levels of several co‑administered drugs.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase terbinafine exposure. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR as terbinafine can enhance anticoagulant effect. - Oral contraceptives: efficacy may be decreased; advise additional contraceptive measures. - Alcohol: concurrent use may heighten risk of liver toxicity. - Cimetidine: may modestly raise terbinafine concentrations. - Antihistamines metabolized by CYP2C9: observe for altered response.